Results: 319 patients had 343 grafts transplanted during the study period. 155/319 patients were alive at 15 years post transplant. Of these 155 patients, 74 are currently alive between 15–20 years, 52 are currently alive beyond 20 years and 29 died. The causes of end-stage liver disease in patients EGFR inhibitor surviving beyond 20 years were autoimmune disease (AIH, PBC and PSC) followed by chronic viral hepatitis (HCV and HBV), fulminant liver failure, and metabolic disease. The primary indication for liver transplantation (p = 0.067) and recipient gender (p = 0.105) did not affect patient survival beyond 20 years. The commonest causes of patient death beyond 15 years were sepsis

(7/29), de-novo malignancy (6/29) and graft dysfunction (6/29). The average age at the time SB203580 in vitro of transplant in recipients surviving 15, 15–20, beyond 20 years is 43.6, 42.6, and 40.6 years of age. The average age of the 29 patients that died beyond 15 years post transplant

was 46.5 years. The average donor age in recipients surviving at 15, 15–20 and beyond 20 years is 33, 34, and 30 years of age respectively. The average donor age in recipients who were deceased beyond 15 years was 35.1 years. The average BMI of recipient surviving at 15, 15–20 and beyond 20 years is 25.7, 25.7, and 25.4. Conclusion: In this study, patients surviving beyond 15 years were not associated with an increasing BMI. Primary indication for liver transplantation and recipient gender did not affect survival beyond 20 years. The greatest threat to long-term survival was due to de-novo malignancy, sepsis and age related complications. VS CHACHAY,1,2 JH MARTIN,3 JB PRINS,1,4 JP WHITEHEAD,4 TM O’MOORE-SULLIVAN,4,5 P LEE,3,5  5-FU ic50 M FRANKLIN,6 K KLEIN,7 PJ TAYLOR,6  M FERGUSON,2,8 JS COOMBES,8 GP THOMAS,1 GJ COWIN,9 CMJ KIRKPATRICK,10 GA MACDONALD,3,11 IJ HICKMAN1,2,4 1The University of Queensland Diamantina Institute*; 2∧Nutrition and Dietetics*; 3School of Medicine Metro-South+*; 4 Mater Medical Research Institute*;

5∧Endocrinology*; 6∧Clinical Pharmacology*; 7Queensland Clinical Trials & Biostatistics Centre+*, 8School of Human Movement Studies+*; 9Centre for Advanced Imaging+*; 10Centre for Medicine Use and Safety, Monash University, Melbourne, Australia. 11∧Gastroenterology and Hepatology*; ∧The Department of – The Princess Alexandra Hospital. +The University of Queensland. *Brisbane, Australia. Corresponding author: v.chachay @uq.edu.au Background: Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease, featuring hepatocyte triglyceride accumulation (steatosis), insulin resistance (IR), dyslipidemia, and increased cardiovascular risk. Potential pharmacological treatment should target both hepatic and cardiometabolic dysregulation. The nutraceutical approach is the use of bioactive food-constituents at pharmacological doses for therapy.